Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for IMARA Inc. (IMRA : NSDQ)
 
 • Company Description   
Imara Inc. is a biopharmaceutical company. It engages in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin. The company's product pipeline consists of IMR-687, which are in clinical stage. Imara Inc. is based in Boston, Massachusetts.

Number of Employees: 41

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.25 Daily Weekly Monthly
20 Day Moving Average: 114,285 shares
Shares Outstanding: 26.28 (millions)
Market Capitalization: $32.85 (millions)
Beta: 2.60
52 Week High: $9.29
52 Week Low: $0.97
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.42% 2.02%
12 Week -21.38% -13.57%
Year To Date -44.44% -32.12%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
116 Huntington Avenue 6th Floor
-
Boston,MA 02116
USA
ph: 617-206-2020
fax: -
ir@imaratx.com http://imaratx.com
 
 • General Corporate Information   
Officers
Rahul D. Ballal - President and Chief Executive Officer; Director
David M. Mott - Chairman of the Board
Michael P. Gray - Chief Financial Officer; Chief Operating Officer
Kenneth Attie - Senior Vice President; Chief Medical Officer
Mark Chin - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 45249V107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/05/22
Share - Related Items
Shares Outstanding: 26.28
Most Recent Split Date: (:1)
Beta: 2.60
Market Capitalization: $32.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.56 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.09 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.45
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 3.45%
vs. Previous Quarter: -5.66%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -69.11
12/31/21 - -63.06
09/30/21 - -75.23
ROA
03/31/22 - -62.88
12/31/21 - -57.93
09/30/21 - -69.32
Current Ratio
03/31/22 - 10.87
12/31/21 - 12.86
09/30/21 - 14.75
Quick Ratio
03/31/22 - 10.87
12/31/21 - 12.86
09/30/21 - 14.75
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 2.76
12/31/21 - 3.27
09/30/21 - 3.78
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©